Clinical Trial

Study of Prognostic Values of Platelet Indices and Inflammatory Markers in Patients With HELLP Syndrome.

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the prognostic values of platelet indices and inflammatory markers in patients with HELLP syndrome as:- :-Primary outcome To investigate prognostic values of platelet indices and. . inflammatory markers in HELLP syndrome patients as main indices including (NLR-PLR-MPV-PDW and RDW). . -Secondary outcome. Evaluation complications of HELLP syndrome including. . * Maternal complication:- eclampsia, disseminated intravascular coagulation (DIC), liver rupture, placental abruption, stroke, and pulmonary or kidney failure. . * Fetal complication:-intra uterine fetal death(iufd) ,neonate need for admission to NICU , congintal anomalies .assess APGAR score (which assess appearance(skin color)-pulse(heart rate)-Grimace(reflex irritability)- Activity(muscle tone)-Respiratory(breathing efforts) or umblical cord PH\<7. .
Trial Details
NCT Number NCT07377786
Lead Sponsor Sohag University
Conditions HELLP Syndrome
Enrollment 60 participants
Start Date 2026-02-01
Primary Completion 2026-08 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-30